ArticleTranslational psychiatry2026
Bisphenol a exposure and major depressive disorder: an integrative analysis combining network toxicology, molecular docking, genetic epidemiology, and transcriptomic validation.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphenol A (BPA) is a widely used endocrine-disrupting chemical that has been implicated in neurodevelopmental and psychiatric disorders; however, the molecular mechanisms linking BPA exposure to major depressive disorder (MDD) remain poorly understood. In this study, we systematically investigated the potential toxicological effects of BPA on MDD by integrating network toxicology, summary-data-based Mendelian randomization (SMR), single-cell RNA sequencing (scRNA-seq), molecular docking, and experimental validation. BPA-related targets were collected from multiple databases and intersected with MDD-associated genes, followed by functional enrichment analyses and construction of a protein-protein interaction network to identify core targets. Causal relationships between candidate targets and MDD were assessed using SMR analysis based on genome-wide association study (GWAS) and expression quantitative trait loci (eQTL) data. Cell-type-specific expression patterns were examined using scRNA-seq data from MDD patients, while molecular docking was employed to evaluate the binding affinities between BPA and core target proteins. Differential expression of key targets was further validated using public bulk RNA-seq datasets, Enzyme-Linked Immunosorbent Assay (ELISA), and BPA exposure were further confirmed via quantitative real-time PCR (qRT-PCR) in BPA-induced MDD mouse models, together with behavioral assessments. A total of 571 shared targets between BPA and MDD were identified, enriched in pathways related to neurodevelopment, synaptic plasticity, and cognitive function. Six core targets (ESR1, SRC, EGFR, AKT1, PLCG2, and JAK3) were highlighted. MR and SMR analyses supported causal roles for AKT1, SRC, PLCG2, and JAK3 in MDD, whereas EGFR exhibited a protective effect. These findings provide integrative evidence for molecular mechanisms underlying BPA-associated susceptibility to MDD and identify potential targets for future therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.